A Phase 2 clinical trial of SK7™ is the first ever study of its kind to be launched in clinics and hospitals across Malaysia, India and Indonesia.
Medika Natura has initiated Phase 2 clinical trials of its proprietary bio-extract SKF7™ in general hospitals and clinics across Malaysia, Indonesia and India. The first clinical trial of its kind for all three countries, these randomized double-blind placebo-controlled studies are aimed at determining SKF7™ efficacy in curtailing obesity in order for it to be classified and marketed as an anti-obesity botanical drug.
A multinational, multi-centered study, this Phase 2 clinical trial was conducted in India in November 2020 and will soon be run in multiple healthcare facilities in Indonesia and Malaysia in March 2021 and June 2021, respectively.
